And Joe and Generex know their Ii-key peptide appr

And Joe and Generex know their Ii-key peptide approach works via numerous studies, illustrating how it increases potency without serious adverse events via peer reviewed reports. As everyone wisely awaits the peptide results specific to Covid-19, we already have similar to SARS and in human studies for cancer. What we need is clearer paths for funding. That avenue has been hard won since we are on the OTC. But eventually progress in opening that runway, although its of course filled with difficulty, will happen. It’s hard to say stay patient when you’ve been a shareholder so long. But that’s the reality of delisting, struggling on otcbb, and a SEC operating in a pandemic. We aren’t Pfizer with billions. We have a management team not even raising funds to enrich their pockets- no pay for years. Every delay most blame them as if they don’t care. That’s nonsense. Let these regulatory filings happen, and funding makes progress quicker. We are closing in on that time.